In Bearbeitung
Lektion 1, Thema 1
In Bearbeitung

Committees

Clinical Governance Committee

The Clinical Governance Committee is a multidisciplinary team across the organisation Chaired by the Chief Clinical Officer. The Committee reports directly to the Healthcare at Home Executive Board via the Clinical Regulatory and Drug Safety Board. The core responsibilities of the Clinical Governance Committee are to:

  • All current and new clinical pathways are in line with good clinical practice and are evidence based.
  • Serious Untoward Incidents are managed with rigour and drives appropriate Corrective Action and Preventive Action (CAPA)
  • Incident trend monitoring drives appropriate CAPA 
  • All HAH clinicians are “fit to practice” in their area of competence. 
  • Relevant audit and contingency plans are evident.

Clinical Governance Committee – Terms of Reference – TOR/CMT/2188

Drug Safety Committee

The Drug Safety Committee is a multidisciplinary team across the organisation Chaired by the Chief Pharmacist. The Committee reports to the Healthcare at Home Executive Board via the Clinical Regulatory and Drug Safety Board. The core responsibilities of the Drug Safety Committee are to;

  • All current and new drug pathways are in line with good clinical practice and are evidence based and are approved by the Clinical Governance Committee.  This includes new medicines and medical devices or changes to any existing service. 
  • HAH storage and distribution practices and drug safety monitoring comply with regulation, this includes alerts and recalls.
  • Serious Untoward Incidents are managed with rigour and drives appropriate CAPA
  • Incident trend monitoring drives appropriate CAPA 
  • HaH are regulatory compliant including all pharmacists and pharmacy technicians are “fit to practice” in their area of competence. 
  • Relevant audit and contingency plans are evident.
  • Appropriate practice in place for the safe provision of medicines and associated ancillaries and devices

Drug Safety Committee – Terms of Reference – TOR/CMT/2983